July 6, 2021:

Big Ten Cancer Research Consortium investigators presented a poster highlighting the BTCRC-AML17-113 study during the American Association for Cancer Research Annual Meeting 2021. Led by John Quigley, MD, of the University of Illinois Cancer Center, the single-arm, open-label, multi-center phase Ib, dose-escalation study examines the safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia.

At the time the abstract was presented in April, researchers reported the study was open to the second dosing cohort and no dose-limiting toxicities had been encountered to date. Researchers reported that enrollment had been negatively impacted by COVID-19 but was expected to improve as vaccinations expand.

The primary goal of the study is to identify the maximum tolerated dose of venetoclax when combined with gemtuzumab ozogamicin. Other study objectives include determining the overall response rate, anti-leukemic activity, relapse-free survival, event-free survival, and overall survival.

The study is currently open to accrual at the University of Illinois Cancer Center; Indiana University Melvin and Bren Simon Comprehensive Cancer Center; and Fred & Pamela Buffett Cancer Center (University of Nebraska).

Study authors include: Saad Arain, Pritesh Patel, Karen Sweiss, Brian Lee Parkin, Heiko Konig, Gregory Calip, Betul Gok Yavuz, and John Quigley.

See abstract.

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The goal of the Big Ten Cancer Research Consortium is to create a unique team-research culture to drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to more than 9,800 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org.